CADL$5.25
$5.30
Chart
Performance
Key Stats
AI CADL Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldCandel Therapeutics exhibits potential in its clinical pipeline but faces significant hurdles with profitability and market adoption. The current price reflects a speculative outlook, requiring careful monitoring of clinical trial results and financing.
Thematic
Candel Therapeutics operates within the growing biopharmaceutical sector with a focus on cancer immunotherapies. The success of its clinical trials and platform technology are key thematic drivers, but the company is still in the early stages of commercialization.
Fundamental
Candel Therapeutics is currently unprofitable with no revenue generation, relying on external financing. The balance sheet shows increasing cash but also significant operating losses. Valuation metrics are not applicable in the traditional sense due to the lack of revenue and earnings.
Technical
The stock shows short-term upward momentum, trading above key moving averages. However, some oscillators suggest it may be approaching overbought territory, indicating a potential for consolidation.
| Factor | Score |
|---|---|
| Cancer Immunotherapy | 75 |
| Biotechnology Innovation | 70 |
| Market Need | 80 |
| Competition | 50 |
| Healthcare Policy & Regulation | 60 |
| Factor | Score |
|---|---|
| Valuation | 30 |
| Profitability | 10 |
| Growth | 0 |
| Balance Sheet Health | 60 |
| Cash Flow | 20 |
| Factor | Score |
|---|---|
| Trend Analysis | 80 |
| Momentum | 65 |
| Volume Confirmation | 70 |
| Support & Resistance | 50 |
| Short-Term Oscillators (15m) | 40 |
AI Investing Checklist
Powered by LiveAIBullish Points (5)
Strong Cash Position
The company has a robust cash and cash equivalents position of $102.65 million as of Q4 2024, providing significant financial flexibility.
Positive Short-Term Momentum
The stock has shown strong recent performance, with a 1-month return of 43.27% and a 5-day return of 5.25%.
Bearish Points (8)
Negative Earnings Per Share (EPS) Trend
EPS for the trailing twelve months (TTM) is -1.33, and several recent quarterly EPS estimates have been negative, indicating ongoing unprofitability.
Lack of Profitability and High P/S Ratio
Revenue for 2024, 2023, and the TTM period is reported as $0.00, leading to extremely high or undefined Price-to-Sales (P/S) ratios (e.g., 2813.8 in 2022), reflecting a lack of commercial sales.
Calendar
August 2025
26
Next Earnings Date
H: $-0.17
A: $-0.17
L: $-0.18
Profile
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase III clinical trials for the treatment of prostate cancer; Phase II clinical trials for the treatment of pancreatic cancer; and Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the?enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
Seasonals
Price Target
21.00 USD
The 39 analysts offering 1 year price forecasts for CADL have a max estimate of 25.00 and a min estimate of 13.00.